Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Mycophenolate mofetil for relapsing-remitting multiple sclerosis.
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease.
Episode 61 with Dr. Yanming Wang on molecular imaging of the myelin sheathing of axons
Mycophenolate mofetil in the treatment of multiple sclerosis: A preliminary report.
The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.
Heartbleed Bug
MS Research Roundup: May 16, 2014
Invitation to Share Your Thoughts on a New MS Research Resource
Viral triggers of multiple sclerosis.
EMD Serono Joins ACP to Launch OPT-UP Study
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.
Episode 42 with Dr. Lawrence Steinman on amyloid in experimental autoimmune encephalomyelitis
Mycophenolate mofetil therapy in the management of inflammatory bowel disease - A retrospective case series and review.
Seeing illness in art and medicine: a patient and printmaker collaboration.
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Episode 49 with Dr. Hugh Rosen on sphingosine 1-phosphate receptor modulators
Positive results from Phase 3 CONFIRM clinical trial show efficacy and safety of oral BG-12 in multiple sclerosis
MS Research Roundup: July 18, 2014
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.
[Recommendations for a brief international cognitive assessment for multiple sclerosis].
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
Episode 37 with Dr. Jeanne Loring on human pluripotent stem cells in a mouse model of MS
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis

Pages